特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
959712

HORA-PDE6B:新興医薬品の考察・市場予測 (2030年)

HORA-PDE6B - Emerging Drug Insight and Market Forecast - 2030

出版日: | 発行: DelveInsight Business Research LLP | ページ情報: 英文 50 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=106.45円
HORA-PDE6B:新興医薬品の考察・市場予測 (2030年)
出版日: 2020年09月08日
発行: DelveInsight Business Research LLP
ページ情報: 英文 50 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

HORA-PDE6Bは、PDE6B遺伝子の変異による網膜色素変性症の治療のために開発された組換えアデノ随伴ウイルス(rAAV)ベクターです。この遺伝子置換療法は、ヒトのPDE6B遺伝子の変異していないコピーを提供して、欠損遺伝子を置換し、桿体外節で機能的なPDE6Bタンパク質の発現を誘導します。 HORA-PDE6Bはウイルス粒子の無菌懸濁液として投与され、網膜下腔に直接注入されます。これにより、桿体(PDE6Bサブユニットが発現)および錐体における導入遺伝子の発現が誘発されます。

当レポートでは、米国、欧州5ヶ国(ドイツ、フランス、イタリア、スペイン、英国)、および日本の7つの主要市場における HORA-PDE6B について詳細に説明し (作用機序、投与量、合成経路、規制のマイルストーンを含む研究開発活動、およびその他の開発活動)、SWOT分析、市場の競合企業、およびその他の新たな治療法を含む将来の市場評価を提供しています。

目次

第1章 医薬品の概要

  • 製品の詳細
  • 作用機序
  • 投薬と管理
  • 研究開発活動
    • 臨床開発
    • 安全性と有効性
  • その他の開発活動

第2章 市場評価

  • 主要7ヶ国市場分析
  • 米国市場
  • ドイツ市場
  • フランス市場
  • イタリア市場
  • スペイン市場
  • 英国市場
  • 日本市場

第3章 SWOT分析

第4章 アナリストの見解

第5章 市場の競合企業

第6章 その他の新しい治療法

第7章 付録

第8章 レポート購入オプション

図表

List of Tables

  • Table 1 HORA-PDE6B, Description
  • Table 2 HORA-PDE6B, Clinical Trial Description
  • Table 3 HORA-PDE6B, 7MM Market Size from 2020 to 2030 (in Million USD)
  • Table 4 Market Competitors
  • Table 5 Other Emerging Therapies

List of Figures

  • Figure 1 The Development Timeline of HORA-PDE6B
  • Figure 2 Patent Details, HORA-PDE6B
  • Figure 3 HORA-PDE6B, 7MM Market Size from 2020 to 2030 (in Million USD)
  • Figure 4 HORA-PDE6B, US Market Size from 2020 to 2030 (in Millions USD)
  • Figure 5 HORA-PDE6B, EU5 Market Size from 2020 to 2030 (in Millions USD)
  • Figure 6 HORA-PDE6B, Japan Market Size from 2020 to 2030 (in Millions USD)
目次
Product Code: DIDM0063

"HORA-PDE6B - Emerging Drug Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Retinitis pigmentosa in 7 Major Markets. A detailed picture of the HORA-PDE6B in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Drug Summary:

HORA-PDE6B is a recombinant adeno-associated viral (rAAV) vector developed for the treatment of retinitis pigmentosa due to a mutation in the PDE6B gene. This gene replacement therapy provides an unmutated copy of the human PDE6B gene to replace the defective gene, in order to induce the expression of a functional PDE6B protein in the rod outer segment. HORA-PDE6B is administered as a sterile suspension of viral particles, injected directly into the subretinal space. This triggers the expression of the transgene in the rods (where the PDE6B subunit is expressed) as well as in the cones.

Scope of the report:

The report provides insights into:

  • A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
  • Elaborated details on regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the drug research and development activity details across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around HORA-PDE6B.
  • The report contains forecasted sales for HORA-PDE6B till 2030.
  • Comprehensive coverage of the late-stage emerging therapies (Phase III) for Retinitis pigmentosa.
  • The report also features the SWOT analysis with analyst insights and key findings of HORA-PDE6B.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

HORA-PDE6B Analytical Perspective by DelveInsight

  • In-depth HORA-PDE6B Market Assessment

This report provides a detailed market assessment of HORA-PDE6B in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.

  • HORA-PDE6B Clinical Assessment

The report provides the clinical trials information of HORA-PDE6B covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights:

  • In the coming years, the market scenario for Retinitis pigmentosa is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence HORA-PDE6B dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Other emerging products for Retinitis pigmentosa are giving market competition to HORA-PDE6B and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of HORA-PDE6B.
  • Our in-depth analysis of the forecasted sales data of HORA-PDE6B from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the HORA-PDE6B.

Key Questions:

  • Which company is developing HORA-PDE6B along with the phase of the clinical study?
  • What is the technology utilized in the development of HORA-PDE6B?
  • What is the product type, route of administration and mechanism of action of HORA-PDE6B?
  • What is the clinical trial status of the study and study completion date?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the HORA-PDE6B development?
  • What are the key designations that have been granted to HORA-PDE6B?
  • What is the forecasted market scenario of HORA-PDE6B?
  • What is the history of HORA-PDE6B and what is its future?
  • What is the forecasted sales of HORA-PDE6B in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What are the other emerging products available and how these are giving competition to HORA-PDE6B?
  • Which are the late-stage emerging therapies under development for the treatment of the PPD?

Table of Contents

1. Drug Overview

  • 1.1. Product Detail
  • 1.2. Mechanism of Action
  • 1.3. Dosage and Administration
  • 1.4. Research and development activity
    • 1.4.1. Clinical Development
    • 1.4.2. Safety and Efficacy
  • 1.5. Other Development Activities

2. Market Assesment

  • 2.1. 7MM Market Analysis
  • 2.2. The United States Market
  • 2.3. Germany Market
  • 2.4. France Market
  • 2.5. Italy Market
  • 2.6. Spain Market
  • 2.7. United Kingdom Market
  • 2.8. Japan Market

3. SWOT Analysis

4. Analyst Views

5. Market Competitors

6. Other Emerging Therapies

7. Appendix

8. Report Purchase Options

株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.